@ serious adverse events were reported in @ ( @ % ) of @ patients who received chemotherapy plus cetuximab ( @ events in @ -LSB- @ % -RSB- patients were treatment-related ) , whereas @ serious adverse events were reported in @ ( @ % ) of @ patients who received chemotherapy alone ( @ events in @ -LSB- @ % -RSB- patients were treatment-related ) .